A new study found that one in three young adults receive medication for opioid use disorder within 12 months of a non-fatal opioid overdose. The study, led by researchers at Boston Medical Center’s Grayken Center for Addiction, in collaboration with the Massachusetts Department of Public Health (DPH), shows which medications…
Alternative to ‘revolving door’ of opioid detox and relapse
In a first-ever randomized trial, patients at a short-term inpatient program began long-term outpatient treatment with buprenorphine before discharge, with better outcomes than detox patients. Three out of four people who complete an inpatient opioid withdrawal management program — commonly known as “detox” — relapse within a month, leading to…
Use Of Buprenorphine To Treat Opioid Addiction Proliferates In California
Buprenorphine, a relative newcomer in the treatment of opioid addiction, is growing in popularity among California doctors as regulatory changes, physician training and other initiatives make the medication more widely accessible. The rate of Medi-Cal enrollees who received buprenorphine nearly quadrupled from the end of 2014 to the third quarter…
Monthly buprenorphine injections effective for opioid use disorders
A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly extended-release injection. Daily dose buprenorphine was approved by the Food and Drug Administration (FDA) in 2002 and has proven to be effective in…
Children’s Accidental Exposure to Buprenorphine on the Rise
Children’s accidental exposure to the opioid addiction medication buprenorphine is increasing, according to new data from U.S. poison control centers. Between 2007 and 2016, poison control centers received 11,275 calls about children’s exposure to buprenorphine, CNN reports. Eighty-six percent of exposures were in children younger than 6, and 89 percent of the…